Bioventus Inc. (BVS)
Valuation Overview•Is Bioventus Inc. Overvalued or Undervalued?
Trading at a relative discount to industry peers, suggesting a specific risk premium is applied.
Moderate quality score of 58/100, reflecting stable operating margins and manageable leverage.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Average quality business weighed down by significant solvency concerns.
Wall Street is highly bullish, projecting significant upside alongside robust expected earnings growth. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
BVS demonstrates adequate business quality with stable profitability. This is paired with a moderately leveraged but stable balance sheet.
The company exhibits steady, low-single-digit revenue growth paired with stable bottom-line earnings. Operating efficiency remains adequate with margins around 10.6%.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $132.1M | -0.9% | +3.5% | +12.1% | — | |
| EBITDA | $20.1M | — | — | — | — | |
| Net Income | $3.1M | +167.8% | — | — | — | |
| EPS (Diluted) | $0.04 | +163.5% | — | -5.6% | — | |
| Free Cash Flow | $8.4M | +89.0% | — | +6.9% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 67.7% | 66.4% | 66.8% | 69.4% |
| Operating Margin | 10.6% | -2.6% | -7.5% | -2.0% |
| Net Margin | 4.9% | -10.8% | -11.8% | -7.4% |
| FCF Margin | 17.5% | 6.9% | 3.7% | 5.8% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.09 | $0.15 | +66.7% | ||
| Q1'26 | $0.22 | $0.24 | +9.1% | ||
| Q4'25 | $0.21 | $0.15 | -30.2% | ||
| Q3'25 | $0.22 | $0.21 | -4.5% | ||
| Q2'25 | $0.06 | $0.08 | +33.3% | ||
| Q1'25 | $0.08 | $0.15 | +87.5% | ||
| Q4'24 | $0.06 | $0.06 | +0.0% | ||
| Q3'24 | $0.07 | $0.19 | +171.4% |
Total return is +68.5% (1Y), outperforming the benchmark by +19.7%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +59.4% | +24.4% | — |
| 1Y | +68.5% | +19.7% | — |
| 3YCAGR | +50.6% | +26.6% | — |
| 5YCAGR | -12.0% | -23.9% | — |
| 10YCAGR | -6.8% | -20.7% | — |
The S&P 500 is at 31.4x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Bioventus Inc. (BVS) valuation, health, and returns.
Based on peer relative multiples, Bioventus Inc. appears Cheap versus peers compared to industry peers.
Bioventus Inc. has multiple valuation anchors: Peer Relative Fair Value: $34.87 | Wall Street Analyst Target: $14.00 (implying +21.8% upside). A convergence of these signals offers higher conviction.
Bioventus Inc. displays fair financial health with a composite quality score of 58/100, supported by a Altman Z-Score of 1.1 (distress zone), Piotroski F-Score of 7/9, Return on Invested Capital (ROIC) of 9.1%.
Bioventus Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Bioventus Inc.'s current growth trajectory is Decelerating. The company achieved -0.9% 1Y revenue growth and +163.5% 1Y EPS growth, compared to its 3Y revenue CAGR of +3.5%.
Wall Street consensus is Buy based on 6 analysts, beating EPS expectations in 67% of recent quarters with a 2-quarter streak. The consensus price target represents a +21.8% change from current levels.
Investment risks for Bioventus Inc. include: -27.5% 1-year max drawdown, elevated distress risk. Volatility risk is characterized by a beta of 0.83x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.